06.27.16
Cobra Biologics, an international CDMO of biologics and pharmaceuticals, has been contracted to develop a second cell line for Alligator Bioscience AB, a Swedish biotechnology company.
Alligator has requested further support from the team at Cobra to develop the cell line for production of new drug candidate ADC-1015, a bispecific immune activator developed to induce superior immune activation. Cobra is using their expression system maxXpress, along with a historically documented master cell bank (CHO-S) and chemically defined media. This delivers a time saving cell line development and clone selection process suitable for GMP manufacture.
In May 2015 Cobra released details of it’s involvement in manufacturing immuno-oncology antibody ADC-1013, as part of Alligator’s Phase 1 trial in advanced solid tumours.
“Cobra has been manufacturing protein therapeutics since 1995 and our maximum protein expression platform, maxXpress, has proven to be very popular to customers looking for both speed and quality,” said Peter Coleman, chief executive officer, Cobra Biologics. “I am delighted that Cobra has the opportunity to continue working with Alligator on their promising clinical programs.”
“Alligator has a long-standing and successful collaboration with Cobra and has seen very good results using their maxXpress system,” said Per Norlén, chief executive officer, Alligator Bioscience. “We are very happy to continue the collaboration with Cobra on our ADC-1015 drug development program.”
Alligator has requested further support from the team at Cobra to develop the cell line for production of new drug candidate ADC-1015, a bispecific immune activator developed to induce superior immune activation. Cobra is using their expression system maxXpress, along with a historically documented master cell bank (CHO-S) and chemically defined media. This delivers a time saving cell line development and clone selection process suitable for GMP manufacture.
In May 2015 Cobra released details of it’s involvement in manufacturing immuno-oncology antibody ADC-1013, as part of Alligator’s Phase 1 trial in advanced solid tumours.
“Cobra has been manufacturing protein therapeutics since 1995 and our maximum protein expression platform, maxXpress, has proven to be very popular to customers looking for both speed and quality,” said Peter Coleman, chief executive officer, Cobra Biologics. “I am delighted that Cobra has the opportunity to continue working with Alligator on their promising clinical programs.”
“Alligator has a long-standing and successful collaboration with Cobra and has seen very good results using their maxXpress system,” said Per Norlén, chief executive officer, Alligator Bioscience. “We are very happy to continue the collaboration with Cobra on our ADC-1015 drug development program.”
